LGVN 2.20 Longeveron Inc.
| Range: | 0.771-23.9 | Vol Avg: | 1286995 | Last Div: | 0 | Changes: | -0.02 |
| Beta: | 0.35 | Cap: | 0.03B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Feb 12 2021 | Empoloyees: | 23 | ||
| CUSIP: | 54303L104 | CIK: | 0001721484 | ISIN: | US54303L1044 | Country: | US |
| CEO: | Mr. Mohamed Wa'el Ahmed Hashad M.B.A. | Website: | https://www.longeveron.com | ||||
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
Stock Details
Neutral 0.03
Longeveron® Lomecel-B™ Data in Alzheimer's Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)
Longeveron Lomecel-B data in Alzheimer's disease selected for late breaking poster present...
globenewswire.com·Mon Oct 14 2024
Positive 0.30
Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting
Longeveron® Lomecel-B 5-Year Long-term Transplant-free Survival Data in HLHS Selected for ...
globenewswire.com·Wed Oct 09 2024
Positive 0.50
Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day
Wa'el Hashad, Chief Executive Officer of Longeveron, will participate in a Fireside Chat a...
globenewswire.com·Mon Oct 07 2024
Positive 0.45
Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
Longeveron management to present at the ROTH Healthcare Opportunities Conference. Speaking...
globenewswire.com·Wed Oct 02 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow